This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Alabama at Birmingham (UAB) to conduct targeted clinical research addressing select viral infections. The $11,514,985.14 definitive contract has a completion date of February 28, 2026 and does not utilize any set-aside designation.
As the prime contractor, UAB will be responsible for participating in protocol development, patient screening and enrollment, and completing clinical study procedures and follow-up. UAB has subcontracted with several academic and research institutions to assist with various aspects of the clinical research, including laboratory testing, transcriptomic data analysis, and clinical site operations. Notable subcontractors include the University of Louisville, University of Mississippi Medical Center, St. Jude Children's Research Hospital, and various children's hospitals and research institutes.
This contract award is part of NIAID's broader efforts to support targeted clinical research to address viral infections and advance medical countermeasures. As a leading academic medical center, UAB has extensive experience conducting biomedical and public health research for federal agencies like NIH, CDC, and DoD, leveraging its expertise across fields like infectious diseases, neuroscience, and health disparities.